Overview

NOV-002 in Myelodysplastic Syndrome (MDS)

Status:
Withdrawn

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to learn if NOV-002 can help to restore bone marrow and blood levels in patients who have MDS. The safety of this drug will also be studied.

Phase:

Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Cellectar Biosciences, Inc.